Targeted Oncology Staff

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

During a live event, Thomas Hutson, DO, PharmD, PhD, and participants discussed current best practice with adjuvant IO post-nephrectomy.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Shagufta Shaheen, MD, discusses treatment strategies for pancreatic NETs.

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.

From pancreatic cancer breakthroughs to pivotal FDA votes, this week’s oncology news highlights progress, setbacks, and shifting regulatory momentum.

Explore the April 2026 FDA oncology roundup: full approval for brexu-cel in MCL, priority reviews for I-DXd and zanidatamab, and key lung cancer NDA news.

Expert insights from Shagufta Shaheen, MD, on sequencing PRRT, everolimus, and cabozantinib after SSA progression in advanced GI NETs, balancing PFS gains and tolerability.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers.

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context.

Clinicians discuss using KEAP1/STK11 mutations to guide CTLA-4 therapy escalation in NSCLC, aiming to overcome PD-1 resistance and improve 5-year survival goals.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

Explore real-world extensive-stage SCLC care, with frontline chemoimmunotherapy, steep therapy attrition, NCCN updates, and evidence favoring 4 chemotherapy cycles.

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in melanoma.

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.

FDA oncology updates spotlight SCLC ADC review, NRG1 cholangiocarcinoma filing, new glioma PET imaging, and trial restart.

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, balancing survival gains, response durability, and real‑world toxicity challenges.

Hutson discusses 3 key clinical trials in RCC: CheckMate 9ER, KEYNOTE-426, and the CLEAR study.

Breast cancer surgery myths, new ALK lung drug filing, safer TIL melanoma prep, ovarian ADC fast track, and statins boosting CAR T outcomes.

During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and safety notes.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

FDA delays Orca‑T review as plixorafenib earns breakthrough status and ATOMIC/ASTEROID data reshape colon and lung cancer care ahead of key Q2 decisions.